Integrated Biosciences
Integrated Biosciences combines synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics targeting age-related diseases. Its proprietary optogenetics platform virtually activates stress responses to discover drugs targeting stressed cells, while deep learning models accelerate small-molecule identification. The company has published AI-driven discoveries of senolytic compounds and a new class of antibiotics.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Cellular stress responses contribute to a range of diseases including neurodegeneration, cancer, diabetes, osteoarthritis, and other age-associated conditions. Existing approaches to targeting these stress responses struggle to identify disease-modifying therapeutics that can effectively mediate healthy aging.
Solution
Integrated Biosciences combines synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics. Its proprietary synthetic biology technology allows researchers to virtually activate cellular stress responses, enabling the discovery of drugs that target stressed cells and the rapid identification of drug targets. The company has also developed next-generation deep learning approaches to identify small molecules, accelerating the drug discovery process for age-related diseases. These capabilities have yielded published discoveries including the first AI-driven discovery of senolytic compounds, a virtual-stress optogenetics platform, and the first AI-driven discovery of a new class of antibiotics.
Target Audience
Integrated Biosciences targets pharmaceutical and biotechnology companies developing therapeutics for age-related diseases, as well as researchers in the fields of aging, neurodegeneration, oncology, and metabolic disease.
Features
- Proprietary optogenetics-based platform for virtually activating cellular stress responses
- Deep learning models for small-molecule identification and drug discovery acceleration
- Drug discovery capability specifically targeting stressed cells
- Rapid drug-target identification using synthetic biology technology
- Published validation including AI-driven senolytic discovery, virtual-stress optogenetics platform, and AI-driven antibiotic discovery
- Current collaboration with Illumina Ventures Labs targeting transcriptome-based therapeutics